DrugPatentWatch Database Preview

Belinostat - Generic Drug Details

« Back to Dashboard

What are the generic sources for belinostat and what is the scope of belinostat patent protection?

Belinostat is the generic ingredient in one branded drug marketed by Spectrum Pharms and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Belinostat has fifty-nine patent family members in twenty-seven countries.

There are five drug master file entries for belinostat. One supplier is listed for this compound.

Summary for belinostat

International Patents:	59
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	5
Suppliers / Packagers:	1
Bulk Api Vendors:	80
Clinical Trials:	44
Patent Applications:	19
DailyMed Link:	belinostat at DailyMed

Pharmacology for belinostat

Drug Class	Histone Deacetylase Inhibitor
Mechanism of Action	Histone Deacetylase Inhibitors

Synonyms for belinostat

(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide

(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

(E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid

(E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide

(E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide

(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-

2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-

2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-

2-Propenamide,N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-,(2E)-

414864-00-9

5OG

866323-14-0

866323-14-0 (E Isomer)

A25012

AB0007889

ABP000140

AC-25046

AKOS025401741

AN-1073

AOB87787

API0003555

AS-17068

AX8144528

BC251660

BCP9000386

BCPP000351

BDBM25150

Beleodaq

Beleodaq (TN)

Belinostat (PXD101)

Belinostat - PXD101

Belinostat (PXD101)

Belinostat [USAN:INN]

Belinostat Ph3

Belinostat,PXD101, PX105684

Belinostat/PXD101,PX105684/

BRD-K17743125-001-01-9

CCG-208758

CHEBI:61076

CHEBI:94531

D0XT6W

DB05015

DTXSID60194378

E-Belinostat

EX-A180

F4H96P17NZ

GTPL7496

J-523584

KB-74881

LS41098

MFCD08064035

MLS006011091

MolPort-009-679-433

N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide

N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide

N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide

N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE

N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide

N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide

N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]-2-propenamide

N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PR

N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE

NCNRHFGMJRPRSK-MDZDMXLPSA-N

NSC-726630

NSC726630

OR190689

PDX-101

PDX101

PubChem22405

PX 105684

PX-105684

PX105684

PX105684, 414864-00-9

PXD 101

PXD-101

PXD101

QCR-181

RL03602

RT-014445

s1085

SC-71101

SMR004702879

UNII-F4H96P17NZ

W-5363

ZINC3818726

US Patents and Regulatory Information for belinostat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y	Y
Spectrum Pharms	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y

International Patents for belinostat

Country	Document Number	Estimated Expiration
China	102579417
South Africa	200710313
Serbia	52214